Form 4: Mineralys Therapeutics Officer Reports Stock Option Exercise and Common Stock Transactions
SEC Form 4 Filing
David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, reports exercising stock options and related transactions involving common stock.
Summary
- On February 12, 2025, David Malcom Rodman, the Chief Medical Officer of Mineralys Therapeutics, Inc., executed transactions involving the company's stock.
- Rodman exercised stock options to acquire 6,348 shares of common stock at a price of $1.08 per share.
- Following these transactions, Rodman directly owns 164,520 shares of common stock.
- Rodman also holds derivative securities, specifically stock options, for 122,229 shares.
- The stock options vest over time, with an initial 25% vesting on July 12, 2022, and the remainder vesting in equal monthly installments over 36 months.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions, which is neutral in sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider trading activity.
Key Dates
| Date | Description |
|---|---|
| July 12, 2022 | 25% of the stock options vested. |
| February 12, 2025 | Date of stock option exercise and common stock transactions. |
| February 13, 2025 | Date of signature for the Form 4 filing. |
| July 11, 2032 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.